MAIA Biotechnology Files 8-K
Ticker: MAIA · Form: 8-K · Filed: Mar 27, 2026 · CIK: 0001878313
Sentiment: neutral
Topics: 8-K, regulation-fd, disclosure
TL;DR
MAIA Biotech dropped an 8-K on 3/27/26 - check it for updates.
AI Summary
MAIA Biotechnology, Inc. filed an 8-K on March 27, 2026, reporting under Regulation FD and other events. The filing includes financial statements and exhibits, with the primary document being the 8-K form itself, along with an exhibit EX-99.1 and associated graphic files. The company's mailing and business address is in Chicago, IL.
Why It Matters
This filing indicates MAIA Biotechnology is providing updates or disclosures to the public, which could contain material information relevant to investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report and does not inherently contain negative news or significant financial distress.
Key Numbers
- 38779 — 8-K Document Size (Size of the main 8-K filing in bytes.)
- 1106 — EX-99.1 Document Size (Size of Exhibit 99.1 in bytes.)
Key Players & Entities
- MAIA Biotechnology, Inc. (company) — Filer
- 0001878313 (company) — CIK
- 2026-03-27 (date) — Filing Date
- 444 WEST LAKE STREET, SUITE 1700 CHICAGO IL 60606 (address) — Mailing and Business Address
FAQ
What specific events or disclosures are being made under Regulation FD?
The filing does not specify the exact content of the Regulation FD disclosure, only that it is being reported under Item 7.01.
What is the nature of the information contained in Exhibit EX-99.1?
Exhibit EX-99.1 is listed as an exhibit to the 8-K filing, but its specific content is not detailed in the provided filing summary.
When was the 8-K filing accepted by the SEC?
The 8-K filing was accepted on March 27, 2026, at 08:00:30.
What is MAIA Biotechnology's state of incorporation and fiscal year end?
MAIA Biotechnology, Inc. is incorporated in Delaware (DE) and has a fiscal year end of December 31 (1231).
What is the SIC code for MAIA Biotechnology, Inc. and its office designation?
The SIC code is 2834 for Pharmaceutical Preparations, and the CF Office is designated as 03 Life Sciences.
Filing Stats: 488 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2026-03-27 08:00:30
Filing Documents
- form8-k.htm (8-K) — 38KB
- ex99-1.htm (EX-99.1) — 1KB
- ex99-1_001.jpg (GRAPHIC) — 2734KB
- 0001493152-26-013088.txt ( ) — 3968KB
- maia-20260327.xsd (EX-101.SCH) — 3KB
- maia-20260327_lab.xml (EX-101.LAB) — 33KB
- maia-20260327_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 27, 2026 MAIA BIOTECHNOLOGY, INC. By: /s/ Vlad Vitoc Name: Vlad Vitoc Title: Chief Executive Officer -3-